Jen Pressler retweeted
Patients have begun treatment in RASolve 308, a global Phase 3 trial evaluating our investigational RAS(ON) G12D-selective inhibitor plus pembrolizumab and platinum-based chemotherapy as first-line treatment for metastatic RAS G12D non-squamous NSCLC.
revmed.com/media/news/13631/…
Jen Pressler retweeted
Today at ESMO26, we presented new subgroup analyses of our multi-selective RAS(ON) inhibitor across RAS variants and treatment settings in previously treated metastatic pancreatic cancer.
Read more: revmed.com/media/news/13651/…
#ForMediaOnly
Jen Pressler retweeted
The U.S. FDA approved the first multi‑selective oral RAS inhibitor in metastatic pancreatic cancer.
More: revmed.com/media/news/13366/…
Jen Pressler retweeted
What does it take to challenge decades of prevailing scientific assumptions?
Watch an exclusive preview of our new documentary series featuring the people working to rethink what's possible in RAS-driven cancers.
#WeAreRevolutionaries #RAS #CancerResearch
Go do great things Luka! Excited for you and the Canes!!
Welcome to the Canes family, @luka_gilbert
🏈: Tight End
🏡: West Chester, Ohio
📚: Lakota West
#GoCanes | #NSD25
2
138
Jen Pressler retweeted
Class of 2024 Senior Video
youtube.com/watch?v=1eFhIvqB…
HHS Lip Dub 2024 HHSTV youtu.be/-2oCW_uFyq8?si=Ms1x… via @YouTube
2
89
Jen Pressler retweeted
PURDUE’S CAMDEN HEIDE WITH THE CRAZY PUTBACK DUNK 😳😳 teapawt.org/d9Hoops/status/1777526…
Congrats guys!
Team @Porter_pressler takes home the 🏆 at today’s flag football tournament! @dognsudsIN on Thursday!
7
306
Jen Pressler retweeted
#PSMAfore Discussant: Using clinical intelligence to define first-line #mCRPC therapy. Presentation by @ChrisSweens1. #ESMO23 written coverage by @zklaassen_md > bit.ly/46BSMbA @myESMO
Jen Pressler retweeted
Homecoming 2023: Congratulations to our homecoming queen & king, Emma Gu and Porter Pressler!!
These Raiders showed up! So proud of these athletes at Bocce State meet. Harrison pride! @RaiderUpdates
Jen Pressler retweeted
Replying to @JournalofNucMed
@JournalofNucMed publishes new consensus statement on patient selection and appropriate use of Lu-177 PSMA-617 radionuclide therapy for the management of management of mCRPC. #ReadNow details on UroToday > bit.ly/45JnHlN @SNM_MI
Jen Pressler retweeted
The @US_FDA has granted fast track designation for our investigational medicine in advanced non-small cell lung cancer (NSCLC). #ADCs #lungcancer
Jen Pressler retweeted
Interesting discussion in @EUplatinum about control arm/design of VISION trial
Ultimately, while Lu-PSMA is highly active (⬆️ PSA RR, PFS, QoL), results from TheraP (not powered for OS) bring into question if it actually ⬆️ OS against "optimal" SOC in 3L mCR #prostatecancer
Jen Pressler retweeted
Dr. Jennifer King discusses state of the art management of post chemotherapy residual nonretroperitoneal disease for Testicular Cancer 👉 onclive.com/view/dr-king-on-… via @onclive @IUCancerCenter @IUSMDeptMed @TCSociety @JenniferKingMD

































